#AUA24 Amer. Urol. Assn. plenary session👉We discussed critical role of the PSMA PET scan in management of #ProstateCancer with biochemical recurrence (BCR), Current Rx with salvage RT, results of Embark & ongoing ARASTEP trial in PSMA-PET+BCR👇Stacy Loeb, MD OncoAlert UroToday.com

🔥 📰 Hot of the press: sharing our work on HRR testing for prostate cancer using US database. Most mCRPC still don't get HRR testing. +pts being tested earlier. Race, age, insurance, low socioecon st, outside academia⏩ low testing Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Rana McKay 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏

Excited to publish Harvard Data Science Review an overview on interpreting randomized controlled trials focusing on information. By prioritizing this fundamental principle, previously obscure statistical concepts reveal their intrinsic beauty: hdsr.mitpress.mit.edu/pub/yb9eq8ja/r…

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉Excellent talk by Heather H. Cheng on who should undergo germ line testing?👉ongoing neoadjuvant trials in germline mutation+ #prostatecancer and take home message👇OncoAlert PCF Science silke gillessen

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉Ana Aparicio ‘s excellent perspective on how to interpret clinical genomic tests👇 and framework for drug development in advanced #prostatecancer & highlights ongoing SWOG Cancer Research Network 2312 trial OncoAlert PCF Science

thankful to Sara Taveras Alam, MD for letting me share this exciting, expansive study on racial disparities in MDS inpatient mortality outcomes at Binaytara Foundation #SCHD24 and Martha Mims for sharing this opportunity w me

Just in BMC 👉Full protocol of our recently initiated, National Cancer Institute RO1 funded, randomized trial of creatine supplementation + Resistance training in advanced #ProstateCancer undergoing ADT Adriana M Coletta, PhD, MS, RD Neli Ulrich, PhD OncoAlert PCF Science Huntsman Cancer Institute UroToday.com

1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

Tian Zhang, MD, MHS Brian F. Chapin CPRIT MD Anderson Cancer Center Tudor Borza Michigan Urology Matt Campbell MD, MS Dr. Andy Wang 🇺🇦 Todd 〽️ Morgan, MD Surena F Matin MD Andy Hahn Excellent talk on step wise approach to implementation science within MUSIC by Tudor Borza I think we can take back very tangibly to our collaborations

Just in 👉data from SWOG Cancer Research Network 1216 trial in mHSPC#prostatecancer👉 PSA level at 3 and 7 months after starting ADT Rx are strongly prognostic of OS: It’s time to design de- or escalation trials based on response biomarkers. OPEN access👉 tinyurl.com/3azhpt4r OncoAlert UroToday.com

Fascinating talk by Nima Sharifi at Chris Wood Symposium on the impact of differential androgen metabolism in men with prostate cancer

Discussion of salvage tx for recurrent RCC after focal therapy at the Chris Wood Symposium by Chad Tang, MD Tian Zhang, MD, MHS and Dr. Karam. Many options, pt selection key

🔥 HOT OFF THE PRESS: Happy to share the results of *two* Phase 2 studies of cabozantinib in #AdrenalCancer in The Lancet Oncology from MD Anderson Cancer Center

Scroll down for more details ⬇️ #GUSM #GUOncology

So proud of mentee Xinmiao Yan for receiving an AACR Scholar in Training Award #AACR24 . Stay tuned for more on her work unraveling the immune hallmarks of #RenalMedullaryCarcinoma .

Thank you to Cancer Discovery for offering us the opportunity to publish our work, simultaneous with #AACR24 ! Grateful to Elizabeth McKenna for facilitating a thoughtful but rapid peer review process to get this out in time for the meeting.
In #kidneycancer , we have been fortunate to have…

1/ Thrilled to share that our paper “Impact of RCC molecular subtypes on immunotherapy & targeted therapy outcomes” is now published in Cancer Cell
Collaborative effort co-led w/ Chris Labaki & Tejas Jammihal under Eli Van Allen Sachet Ashok Shukla Toni Choueiri, MD David Braun ‘s mentorship…

How can you critically evaluate clinical prostate cancer genomic test reports, and learn to spot red flags? Check out this piece by Gillian Vandekerkhove, Veda Giri, and colleagues in JCO Precision Oncology ascopubs.org/doi/10.1200/PO…. Thanks to PCF Science for support!

'Embracing #cancer complexity: Hallmarks of systemic disease'

It was a privilege to contribute to this #Cell review, with an incredible group of scientists!

Our forward-looking perspective ⬇️ - incl. the #tumor #microenvironment as a critical target 🎯

cell.com/cell/fulltext/…

Excited to share our new study finding that the quality of subgroup analyses and claims for differential treatment effects in modern phase III oncology trials remains low, increasing risk of misinterpretation. More use of frameworks such as ICEMAN may improve future quality.

Excited to share our new manuscript on outcomes with tivozanib in RCC post-ICI, cabo, and len! Benefit limited to pts w/ indolent disease and prior prolonged TKI therapy. Thanks to Dr. Tannir Pavlos Msaouel Andy Hahn Matt Campbell MD, MS for your support!
academic.oup.com/oncolo/article…